Table 3.

HRs and Corresponding 95% CIs for Recurrence at Baseline and at Years 1 and 2 of Remission^a

Characteristic	Baseline (N = 404)		Year 1 (n = 281)		Year 2 (n = 219)
	HRb	95% CI	HRb	95% CI	HRb	95% CI
Race
White	1.0	ref	1.0	ref	1.0	ref
African-American	0.56	0.21 to 1.50	0.76	0.24 to 2.41	1.21	0.29 to 5.11
Other	0.51	0.07 to 3.68	1.06	0.14 to 7.87	—	—
Education
Non–high school graduate	1.0	ref	1.0	ref	1.0	ref
High school graduate	1.45	0.87 to 2.43	1.72	0.76 to 3.90	5.46	0.72 to 41.48
Post–high school	1.24	0.74 to 2.05	1.53	0.68 to 3.42	4.78	0.63 to 36.19
Yearly Income, $
≥ 90,000	1.0	ref	1.0	ref	1.0	ref
50,000 to < 90,000	1.55	0.94 to 2.56	0.88	0.49 to 1.57	1.16	0.45 to 3.01
25,000 to < 50,000	1.71	1.03 to 2.84	0.70	0.37 to 1.32	0.71	0.24 to 2.12
< 25,000	1.52	0.89 to 2.60	0.88	0.46 to 1.69	1.35	0.48 to 3.78
Could not be assessed	1.65	0.92 to 2.95	0.83	0.39 to 1.76	1.08	0.33 to 3.56
Body mass index, in kg/m2
< 25	1.0	ref	1.0	ref	1.0	ref
25 to < 30	1.14	0.83 to 1.57	0.84	0.53 to 1.34	0.86	0.42 to 1.78
≥ 30	0.95	0.69 to 1.30	0.68	0.42 to 1.08	0.67	0.32 to 1.38
Smoking status
Never smoker	1.0	ref	1.0	ref	1.0	ref
Former smoker	0.88	0.66 to 1.18	1.06	0.69 to 1.63	0.98	0.51 to 1.89
Current smoker	0.93	0.63 to 1.38	1.26	0.73 to 2.18	0.95	0.38 to 2.35
Alcohol use, drinks per week
≤ 7	1.0	ref	1.0	ref	1.0	ref
8 to ≤ 14	0.97	0.61 to 1.55	0.90	0.45 to 1.79	1.37	0.57 to 3.24
≥ 15	0.89	0.52 to 1.54	0.78	0.34 to 1.78	0.33	0.04 to 2.39
Family history
None	1.0	ref	1.0	ref	1.0	ref
Breast only	0.84	0.58 to 1.22	0.89	0.53 to 1.51	1.15	0.55 to 2.40
Ovarian only	0.69	0.34 to 1.40	0.73	0.27 to 1.98	0.47	0.06 to 3.40
Breast and ovarian	3.24	1.19 to 8.78	4.22	1.02 to 17.41	13.87	1.81 to 105.96
Menopausal status
Premenopausal	1.0	ref	1.0	ref	1.0	ref
Postmenopausal	1.15	0.75 to 1.78	1.12	0.60 to 2.08	1.10	0.44 to 2.78
Stagec
I	1.0	ref	1.0	ref	1.0	ref
II	3.45	1.70 to 7.0	3.09	1.25 to 7.63	2.15	0.51 to 9.07
III	12.59	7.38 to 21.50	12.27	6.31 to 23.87	14.77	5.74 to 38.02
IV	16.10	8.41 to 30.82	11.00	4.14 to 29.21	4.21	0.49 to 36.47
Primary site
Ovarian	1.0	ref	1.0	ref	1.0	ref
Peritoneal	1.70	1.11 to 2.61	2.72	1.53 to 4.85	5.32	2.32 to 12.19
Fallopian	0.78	0.45 to 1.38	0.94	0.44 to 2.05	0.65	0.15 to 2.69
Could not be assessed	1.64	0.60 to 4.47	1.06	0.15 to 7.73	3.00	0.39 to 23.04
Grade
Well differentiated	1.0	ref	1.0	ref	1.0	ref
Moderately differentiated	3.37	1.52 to 7.44	2.52	0.96 to 6.61	2.23	0.47 to 10.60
Poorly differentiated	5.06	2.36 to 10.85	3.92	1.57 to 9.79	4.98	1.17 to 21.15
Could not be assessed	3.41	1.41 to 8.24	2.12	0.67 to 6.70	3.31	0.60 to 18.10
Histology
Serous	1.0	ref	1.0	ref	1.0	ref
Endometrioid	0.22	0.13 to 0.37	0.23	0.12 to 0.44	0.13	0.04 to 0.42
Mucinous	0.04	0.01 to 0.28	—	—	—	—
Clear cell	0.21	0.10 to 0.44	0.30	0.13 to 0.70	0.19	0.05 to 0.80
Brenner	0.36	0.09 to 1.47	0.32	0.04 to 2.31	0.59	0.08 to 4.36
MMT	0.44	0.16 to 1.20	0.40	0.10 to 1.62	0.39	0.05 to 2.86
Mixed	0.46	0.28 to 0.75	0.37	0.18 to 0.77	0.38	0.13 to 1.08
Otherd	1.17	0.28 to 4.86	1.48	0.19 to 11.27	—	—
Could not be assessed	0.87	0.44 to 1.70	0.39	0.10 to 1.60	0.87	0.21 to 3.66
Pretreatment CA-125
≤ 35 U/mL	1.0	ref	1.0	ref	1.0	ref
> 35 U/mL	2.92	1.75 to 4.89	2.35	1.21 to 4.58	2.27	0.88 to 5.87
Could not be assessed	2.93	1.64 to 5.22	2.96	1.40 to 6.26	2.24	0.71 to 7.07
Pretreatment pleural effusion
No	1.0	ref	1.0	ref	1.0	ref
Yes	1.98	1.22 to 3.24	3.66	1.53 to 8.75	17.02	2.04 to 141.74
Could not be assessed	0.97	0.66 to 1.44	1.91	0.92 to 3.96	7.64	1.04 to 55.97
Cytology of ascites/pelvic washings
Negative	1.0	ref	1.0	ref	1.0	ref
Positive	5.49	3.72 to 8.09	5.58	3.33 to 9.36	4.67	2.20 to 9.91
Atypical	3.20	1.52 to 6.70	2.91	0.99 to 8.56	3.09	0.67 to 14.15
Could not be assessed	3.52	2.21 to 5.59	3.02	1.59 to 5.77	3.68	1.53 to 8.84
Pretreatment ascites
No	1.0	ref	1.0	ref	1.0	ref
Yes	2.85	2.08 to 3.89	2.77	1.79 to 4.29	2.97	1.52 to 5.81
Could not be assessed	1.10	0.27 to 4.50	2.00	0.48 to 8.41	2.54	0.33 to 19.73
Lymph node involvement
No palpable nodes, no biopsies	1.0	ref	1.0	ref	1.0	ref
Palpable nodes, no biopsies	1.48	0.64 to 3.38	5.39	2.10 to 13.82	6.53	0.84 to 50.92
Biopsies negative	0.30	0.22 to 0.42	0.36	0.23 to 0.58	0.43	0.21 to 0.88
Biopsies positive	1.16	0.82 to 1.64	1.41	0.84 to 2.37	2.06	0.93 to 4.56
Could not be assessed	0.59	0.19 to 1.87	—	—	—	—
Synchronous primary tumor
No	1.0	ref	1.0	ref	1.0	ref
Yes, endometrial	0.42	0.17 to 1.01	0.16	0.02 to 1.18	0.36	0.05 to 2.61
Yes, othere	1.20	0.44 to 3.25	1.61	0.39 to 6.66	—	—
Residual disease after cytoreductive surgeryf
No	1.0	ref	1.0	ref	1.0	ref
Yes	4.82	3.59 to 6.48	5.02	3.29 to 7.66	4.54	2.34 to 8.78
Could not be assessed	5.31	3.39 to 8.32	6.99	3.73 to 13.10	9.71	3.61 to 26.09
Size of residual disease after cytoreductive surgery, cmf
No residual disease	1.0	ref	1.0	ref	1.0	ref
0.1 to < 1.0	4.41	3.12 to 6.22	5.23	3.21 to 8.5	4.43	1.96 to 10.04
1.0 to < 2.0	5.62	3.50 to 9.02	6.86	3.32 to 14.19	11.12	3.77 to 32.84
≥ 2.0	6.72	3.85 to 11.75	1.40	0.19 to 10.18	2.76	0.37 to 20.51
Could Not Be Assessed	4.89	3.37 to 7.11	5.87	3.47 to 9.92	5.54	2.36 to 12.99
Debulking at cytoreductive surgeryg
Optimal	1.0	ref	1.0	ref	1.0	ref
Suboptimal	3.77	2.72 to 5.22	3.40	2.01 to 5.77	4.60	2.02 to 10.48
Received neoadjuvant chemotherapy	2.99	1.89 to 4.72	1.31	0.48 to 3.58	2.50	0.76 to 8.20
No primary surgery performed	1.70	0.42 to 6.95	—	—	—	—
Unknown	3.76	1.91 to 7.40	4.27	1.56 to 11.70	3.60	0.49 to 26.39
Platinum chemotherapy, no. of cyclesh,i
No	1.0	ref	1.0	ref	1.0	ref
0 to ≤ 3	2.21	0.63 to 7.85	3.80	0.74 to 19.59	2.33	0.39 to 13.93
3 to ≤ 6	5.66	2.09 to 15.31	6.29	1.54 to 25.70	2.38	0.56 to 10.11
> 6	9.96	3.64 to 27.24	10.72	2.57 to 44.76	6.59	1.51 to 28.67
Yes, number of cycles unknown	2.46	0.27 to 22.02	5.14	0.46 to 56.88	—	—
Taxane chemotherapy, no. of cycles)h,j
No	1.0	ref	1.0	ref	1.0	ref
0 to ≤ 3	1.50	0.54 to 4.14	1.34	0.36 to 4.99	1.66	0.33 to 8.23
3 to ≤ 6	3.52	1.72 to 7.19	2.96	1.19 to 7.36	2.15	0.65 to 7.14
> 6	6.82	3.29 to 14.14	6.03	2.35 to 15.47	4.49	1.27 to 15.92
Yes, number of cycles unknown	1.84	0.39 to 8.66	2.95	0.57 to 15.23	2.54	0.26 to 24.67
Other chemotherapy, no. of cyclesh,k
No	1.0	ref	1.0	ref	1.0	ref
0 to ≤ 3	1.01	0.32 to 3.16	1.53	0.38 to 6.24	—	—
3 to ≤ 6	1.75	1.03 to 2.98	2.59	1.25 to 5.36	3.90	1.38 to 11.00
> 6	2.29	1.39 to 3.78	2.13	0.93 to 4.88	4.34	1.53 to 12.31
Yes, number of cycles unknown	4.66	1.72 to 12.64	18.13	4.28 to 76.72	—	—
Maintenance chemotherapy
No	1.0	ref	1.0	ref	1.0	ref
Yes	1.79	1.21 to 2.64	3.51	2.15 to 5.71	3.43	1.51 to 7.78
Number of chemotherapy cycles before normalization of CA-125
Normalized without/prior to chemotherapy	1.0	ref	1.0	ref	1.0	ref
1 to < 3	2.56	1.71 to 3.84	1.80	1.06 to 3.05	2.29	1.08 to 4.85
3 to < 6	5.59	3.72 to 8.39	4.33	2.50 to 7.52	4.23	1.78 to 10.08
≥ 6	5.19	3.19 to 8.43	4.51	2.27 to 8.96	2.17	0.48 to 9.72
Could not be assessed	2.94	1.75 to 4.95	2.26	1.12 to 4.58	1.91	0.61 to 5.91
Persistent disease after primary treatment
No	1.0	ref	1.0	ref	1.0	ref
Yes	2.96	1.57 to 5.60	0.84	0.12 to 6.0	—	—

Abbreviations: HR, hazard ratio; MMT, mixed Mullerian tumor; ref, reference.

^aLandmark method was used for years 1 and 2. Please see Tables 1 and 2 for number of participants in the different categories.

^bHRs were calculated using Cox regression models adjusted for current age (continuous) and disease-free survival was measured from the specified time point.

^cOne patient was missing stage information because she never had staging or cytoreductive surgeries and was never formally staged by oncologist.

^dIncludes one micropapillary serous, one adenosquamous, one papillary serous with multiple psammoma bodies.

^eIncludes one of each of the following synchronous cancers: fallopian tube, granulosa cell tumor of the ovary, recurrent breast, GI stromal, skin, and appendiceal.

^fExcludes three patients that did not have cytoreductive surgery.

^gPatients were considered to be optimally debulked if their disease was <1 cm or their surgeon/oncologist declared them to be optimally debulked at the conclusion of their cytreductive surgery.

^hIncludes neoadjuvant, adjuvant and maintenance chemotherapies received as well as any chemotherapy received for persistent disease.

ⁱIncludes carboplatin, cisplatin, oxaliplatin, and abraxane.

^jIncludes taxol, taxotere, and xyotax.

^kIncludes avastin, doxil, topotecan, gemzar, cytoxan, interferon, mytomycin, erbitux, ifosphomaide, catumaxomab, and ovarex. Many of these other chemotherapies were given as part of a clinical trial and in some cases it was unclear whether participants received placebo or the active agent; cases that were reported to have gotten the placebo were considered to have received no chemotherapy.